NCT06079333: NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study)
- State
- Under way
- Phase
- Phase 2
- People
- 20 planned
- Started
- 1 Jan 2023
- Primary completion
- 1 Jan 2027
- Arms
- neo-adjuvant and adjuvant braf/mek-inhibition
- Results
- None posted
- 1 Jan 2023: Trial started
- 12 Oct 2023: Trial registered